CARsgen partners with Shanghai Cancer Institute to advance CAR-T therapies
30 September 2015 | By Victoria White
The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies...
List view / Grid view
30 September 2015 | By Victoria White
The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies...
29 September 2015 | By Victoria White
Congenica’s platform Sapientia has been developed to analyse and interpret whole genome data. With this grant Congenica will be able to extend its capability to include other types of -omics data...
29 September 2015 | By Victoria White
LA Cell has exclusively licensed technology that enables modified monoclonal antibodies to penetrate into cells and target "undruggable" disease-causing molecules...
29 September 2015 | By Victoria White
The funds will enable Apitope to progress the clinical development of its innovative pipeline which includes therapies for Factor VIII intolerance in Haemophilia A patients...
29 September 2015 | By Victoria White
Preclinical data showed that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation...
29 September 2015 | By Victoria White
LDC and Infinity will work together to select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network...
28 September 2015 | By Victoria White
The newly described Cpf1 system differs in several important ways from Cas9, with significant implications for research and therapeutics...
28 September 2015 | By Victoria White
The $5.5 million grant will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor...
28 September 2015 | By Victoria White
H7N9 candidate vaccines have failed to elicit a strong immune response necessary to protect from infection. A study has revealed that it may be due to immune camouflage...
28 September 2015 | By Victoria White
The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research with a drug candidate in a proof-of-concept disease model of allergic asthma...
25 September 2015 | By Victoria White
Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists...
25 September 2015 | By Victoria White
TLR agonists are promising agents that activate innate immune cells and enhance the visibility of cancer tumours...
25 September 2015 | By Victoria White
Researchers discovered that FAK inhibition can modulate the balance of immune cells in a tumour enabling an immune response to destroy the cancer cells...
25 September 2015 | By Victoria White
When eCD4-lg was tested in animal models, the results were so powerful and effective that they suggested the compound’s potential to serve the role of an alternative HIV/AIDS vaccine...
25 September 2015 | By Victoria White
The team of researchers will comprehensively study human proteomes with the aim of turning the vast amount of molecular information into designs for new reagents, equipment, workflows, assays and software...